ALS drug trial pulled before it even started
NCT ID NCT03508453
First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This was a planned phase 2 trial to test IC14, a monoclonal antibody, in 50 people with rapidly progressing ALS. Participants would have received intravenous IC14 or placebo twice weekly for 12 weeks. The study was withdrawn before any patients were enrolled, so no data on safety or effectiveness were collected.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
IC14 (a monoclonal antibody)
What this could lead to
If it had worked, this could point toward a treatment that slows progression of rapidly progressive ALS.
What could go wrong
This trial was withdrawn before enrolling any participants, so no results are available. Early-phase trials often fail to show benefit in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Royal Brisbane and Women's Hospital
Herston, Queensland, 4006, Australia